These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 29610997)

  • 1. Rechallenge treatment with a platinum-based regimen in patients with sensitive relapsed small-cell lung cancer.
    Naito Y; Yamada K; Imamura Y; Ishii H; Matsuo N; Tokito T; Kinoshita T; Azuma K; Hoshino T
    Med Oncol; 2018 Apr; 35(5):61. PubMed ID: 29610997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
    Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
    Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer.
    Wakuda K; Kenmotsu H; Naito T; Akamatsu H; Ono A; Shukuya T; Nakamura Y; Tsuya A; Murakami H; Takahashi T; Endo M; Nakajima T; Yamamoto N
    Am J Clin Oncol; 2015 Feb; 38(1):28-32. PubMed ID: 23388567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
    Igawa S; Shirasawa M; Fukui T; Nishinarita N; Sone H; Ozawa T; Sugita K; Okuma Y; Kurahayashi S; Ono T; Sugimoto A; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
    Oncology; 2018; 94(4):207-214. PubMed ID: 29393275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer.
    Okuma HS; Horinouchi H; Kitahara S; Asao T; Sunami K; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Ohe Y
    Clin Lung Cancer; 2017 Mar; 18(2):234-240.e2. PubMed ID: 27867001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.
    Inoue A; Sugawara S; Maemondo M; Mori Y; Oizumi S; Harada M; Taima K; Morikawa N; Ishida T; Kinoshita I; Watanabe H; Suzuki T; Nakagawa T; Saito R; Nukiwa T
    Lung Cancer; 2015 Jul; 89(1):61-5. PubMed ID: 26004087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of Efficacy and Safety of Different Therapeutic Regimens as 
Second-line Treatment for Small Cell Lung Cancer].
    Li Z; Liu X; Li J; Gao H; Tang C; Li X; Guo W; Qin H; Wang W; Qu L; Chen J
    Zhongguo Fei Ai Za Zhi; 2015 May; 18(5):280-8. PubMed ID: 25975298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
    Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
    Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer.
    Hirose T; Nakashima M; Shirai T; Kusumoto S; Sugiyama T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Adachi M
    Lung Cancer; 2011 Sep; 73(3):345-50. PubMed ID: 21277039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of post-progression survival on overall survival among patients with sensitive relapse of small cell lung cancer.
    Miura Y; Imai H; Sakurai R; Kaira K; Sunaga N; Minato K; Saito R; Hisada T
    Med Oncol; 2018 Mar; 35(4):45. PubMed ID: 29508094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Second-line Chemotherapy in Patients With Sensitive Relapsed Small-cell Lung Cancer.
    Wakuda K; Miyawaki T; Miyawaki E; Mamesaya N; Kawamura T; Kobayashi H; Omori S; Nakashima K; Ono A; Kenmotsu H; Naito T; Murakami H; Mori K; Endo M; Takahashi T
    In Vivo; 2019; 33(6):2229-2234. PubMed ID: 31662561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy with carboplatin and paclitaxel for small cell lung cancer.
    Mouri A; Yamaguchi O; Miyauchi S; Shiono A; Utsugi H; Nishihara F; Murayama Y; Kagamu H; Kobayashi K
    Respir Investig; 2019 Jan; 57(1):34-39. PubMed ID: 30528688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel as third-line chemotherapy for small cell lung cancer failing both etoposide- and camptothecin-based chemotherapy.
    Kim SH; Kim MJ; Kim YJ; Chang H; Kim JW; Lee JO; Lee KW; Kim JH; Bang SM; Lee JS
    Medicine (Baltimore); 2017 Oct; 96(42):e8176. PubMed ID: 29049199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy.
    Ishii H; Azuma K; Kawahara A; Matsuo N; Tokito T; Hoshino T
    Invest New Drugs; 2021 Feb; 39(1):269-271. PubMed ID: 32783090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rechallenge with First-Line Platinum Chemotherapy for Sensitive-Relapsed Small-Cell Lung Cancer.
    Shiozawa T; Sekine I; Aida Y; Watanabe H; Nakazawa K; Kurishima K; Satoh H; Hizawa N
    Case Rep Oncol; 2018; 11(3):622-632. PubMed ID: 30323752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia-inducible factor-1α and excision repair cross-complementing 1 in patients with small cell lung cancer who received front-line platinum-based chemotherapy: a retrospective study.
    Lee GW; Go SI; Cho YJ; Jeong YY; Kim HC; Duk Lee J; Hwang YS; Ko GH; Lee JH; Kim DC; Yang JW; Oh S; Lee JS
    J Thorac Oncol; 2012 Mar; 7(3):528-34. PubMed ID: 22258474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-agent chemotherapy compared with combination chemotherapy as second-line treatment in extensive-stage small cell lung cancer: a retrospective analysis.
    Song Z; Shao L; Lin B; Zhang Y
    Clin Transl Oncol; 2013 Oct; 15(10):843-8. PubMed ID: 23423808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE).
    Salama JK; Gu L; Wang X; Pang HH; Bogart JA; Crawford J; Schild SE; Vokes EE; Ready NE
    J Thorac Oncol; 2016 Mar; 11(3):361-9. PubMed ID: 26723241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic effects and prognostic factors for the limited-stage small cell lung cancer treated with multidisciplinary therapy].
    Dong XJ; Wang MZ; Zhong W; Zhang L; Zhang XT; Zhao J; Xia Y; Li LY
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):216-21. PubMed ID: 22780978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis.
    Jiang S; Huang L; Zhen H; Jin P; Wang J; Hu Z
    BMC Cancer; 2021 Dec; 21(1):1308. PubMed ID: 34876060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.